Molecular characterization of non-small-cell lung cancer (NSCLC) is essential to define the
correct therapeutic algorithm in metastatic disease. Approximately 90% of epidermal growth …

The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …

Simple Summary The present study showed the comprehensive analysis of disease
characteristics and treatment patterns in uncommon EGFR mutation-positive NSCLC at a …

The identification of activating mutations in the tyrosine kinase domain of the EGF receptor
(EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic …

Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most …

Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the
detection of actionable mutations, which has revolutionized the treatment paradigm in this …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …

One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …

Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …